AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Skyrizi (risankizumab) by Year
Skyrizi (risankizumab) — Worldwide reported growth YoY (%) (%)
AbbVie Skyrizi (risankizumab): 49.9% in FY2025, down 1.0 pts from a year earlier.
Latest, FY2025
49.9%
Period ended Dec 31, 2025
Change on a year earlier
-1.0 pts
50.9% in FY2024
History
5 years
Since FY2021
Sources
5
Documents cited below
Where the FY2025 figure comes from
“|| Skyrizi | 15,202 | 2,360 | 17,562 | 50.7 | 44.6 | 49.9 | 43.0 | 49.7”
Source: Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Reported in Form 8-K Key Product Revenues Schedule.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Skyrizi (risankizumab) — Worldwide reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 49.9% | -1.0 pts | Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗ |
| FY2024 | Dec 31, 2024 | 50.9% | +0.6 pts | Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗ |
| FY2023 | Dec 31, 2023 | 50.3% | -25.4 pts | Form 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗ |
| FY2022 | Dec 31, 2022 | 75.7% | -9.2 pts | Form 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗ |
| FY2021 | Dec 31, 2021 | 84.9% | – | Form 8-K (abbv-20211231xexhibit991.htm, filed 2022-02-02) ↗ |
Cite this data
StockData. (2026). AbbVie Skyrizi (risankizumab) (%), annual FY2021–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/skyrizi-ww-rep-yoy
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.